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MaBACKGROUND The role of patient age in the efﬁcacy of mesenchymal stem cell (MSC) therapy in ischemic
cardiomyopathy (ICM) is controversial.
OBJECTIVES This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even
in older subjects.
METHODS Patients with ICM who received MSCs via transendocardial stem cell injection (TESI) as part of the TAC-HFT
(Transendocardial Autologous Cells in Ischemic Heart Failure) (n ¼ 19) and POSEIDON (Percutaneous Stem Cell Injection
Delivery Effects on Neomyogenesis) (n ¼ 30) clinical trials were divided into 2 age groups: younger than 60 and 60 years
of age and older. Functional capacity was measured by 6-min walk distance (6MWD) and quality of life using the Min-
nesota Living With Heart Failure Questionnaire (MLHFQ) score, measured at baseline, 6 months, and 1 year post-TESI.
Various cardiac imaging parameters, including absolute scar size, were compared at baseline and 1 year post-TESI.
RESULTS The mean 6MWD was similar at baseline and increased at 1 year post-TESI in both groups: 48.5  14.6 m
(p ¼ 0.001) for the younger and 35.9  18.3 m (p ¼ 0.038) for the older participants (p ¼ NS between groups). The older
group exhibited a signiﬁcant reduction inMLHFQ score (7.04 3.54; p¼0.022), whereas the younger than 60 age group
had a borderline signiﬁcant reduction (11.22  5.24; p ¼ 0.058) from baseline (p ¼ NS between groups). Although there
were signiﬁcant reductions in absolute scar size from baseline to 1 year post-TESI, the effect did not differ by age.
CONCLUSIONS MSC therapy with TESI in ICM patients improves 6MWD and MLHFQ score and reduces myocardial
infarction size. Importantly, older individuals did not have an impaired response to MSC therapy. (J Am Coll Cardiol
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TABLE 1 Baseline C
Age at transplantatio
Time from MI to ther
Sex
Male
Female
Race
White
European
White North Americ
Western European
Black
Indian/South Asian
Filipino (Pilipino)
Native American
White Caribbean
Ethnicity
Hispanic or Latino
Not Hispanic or Lat
Unknown
6MWD
MLHFQ total score
Scar size as absolute
Scar size as % of LV
EF
EDV
ESV
SI
Values are mean  SD or
6MWD ¼ 6-min walk d
systolic volume; LV ¼ le
With Heart Failure Quest
ABBR EV I A T I ON S
AND ACRONYMS
6MWD = 6-min walk distance
CI = conﬁdence interval
EDV = end-diastolic volume
EF = ejection fraction
ESV = end-systolic volume
hMSC = human mesenchymal
stem cell
ICM = ischemic cardiomyopathy
LV = left ventricular
MI = myocardial infarction
MLHFQ = Minnesota Living
With Heart Failure
Questionnaire
MSC = mesenchymal stem cell
TESI = transendocardial stem
cell injection
Golpanian et al. J A C C V O L . 6 5 , N O . 2 , 2 0 1 5
Effect of Aging on hMSC Therapy in Ischemic Cardiomyopathy J A N U A R Y 2 0 , 2 0 1 5 : 1 2 5 – 3 2
126(13–16). Accordingly, these age-related im-
pairments suggest that MSC therapy might
produce a reduced effect when the cells are
derived from older individuals.SEE PAGE 148Although some proponents believe that
advanced stem cell donor age results in
diminished function (17–21), other studies
raise a clinically relevant issue as to whether
recipient age is a crucial factor limiting the
response to cell therapy (22–24). This has led
to the notion that MSC therapy outcome de-
pends not only on stem cell age, and thus
function, but also recipient age and comor-
bidities (9,22). Indeed, reduced responsive-
ness as a function of donor age would be a
major limitation to the emerging develop-
ment of cell therapy for heart disease, giventhe increasing incidence and morbidity of heart dis-
ease with age (25). Here, we tested the hypothesisharacteristics
Age Group
p Value
<60 yrs
(n ¼ 23)
$60 yrs
(n ¼ 26)
n, yrs 51.95  7.33 68.86  4.51 <0.0001
apy, yrs 6.26  6.42 15.43  9.23 0.0002
1.000
21 (42.9) 23 (46.9)
2 (4.1) 3 (6.1)
0.1547
12 (24.5) 19 (38.8)
0 (0.0) 1 (2.0)
an 3 (6.1) 1 (2.0)
0 (0.0) 1 (2.0)
2 (4.1) 0 (0.0)
0 (0.0) 1 (2.0)
1 (2.0) 0 (0.0)
0 (0.0) 1 (2.0)
5 (10.2) 2 (4.1)
0.0629
9 (18.4) 4 (8.2)
ino 14 (28.6) 20 (40.8)
0 (0.0) 2 (4.1)
418.30  71.57 372.12  93.01 0.0561
42.33  28.84 31.58  27.81 0.2013
value 26.93  15.35 21.47  13.29 0.2080
mass 22.09  13.55 11.79  6.06 0.0041
31.96  6.22 29.49  12.65 0.3945
289.36  81.65 274.40  86.66 0.5525
199.50  68.53 199.29  86.15 0.9930
0.50  0.07 0.47  0.11 0.3077
n (%).
istance; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-
ft ventricular; MI ¼ myocardial infarction; MLHFQ ¼ Minnesota Living
ionnaire.that improvements in functional capacity, quality of
life, and reverse remodeling by transendocardial in-
jection of hMSCs in patients with ICM is actually
preserved with recipient age. Our data here derive
from the phase I/II randomized trials of TAC-HFT
(Transendocardial Autologous Cells in Ischemic
Heart Failure) (26) and POSEIDON (Percutaneous
Stem Cell Injection Delivery Effects on Neomyo-
genesis) (27) trials.
METHODS
Data from the TAC-HFT and POSEIDON trials were
collected in a similar fashion in a central electronic
data system. All ICM patients who received hMSCs
from these trials were pooled together and dichoto-
mized into 2 age groups, younger than 60 years of age
and 60 years of age and older. The associations be-
tween age and both clinical and imaging parameters
were assessed. Values of p < 0.05 were considered
signiﬁcant. Comprehensive statistical methods can be
found in the Online Appendix.
RESULTS
A total of 49 patients who received hMSCs from
both trials are included in this analysis. Thirty pa-
tients received hMSCs in the POSEIDON trial, of
whom 11 patients (36.7%) were younger than 60
years of age and 19 patients (63.3%) were 60 years
of age and older. In the TAC-HFT trial, a total of 19
patients received hMSCs, with 12 (63.2%) younger
than 60 years of age and 7 patients (36.8%) were 60
years of age and older. The average age at trans-
plantation was 51.95  7.33 years (range: 32.48 to
59.91 years) in the younger than 60 years age group
and 68.86  4.51 years (range: 62.84 to 79.01 years)
in the older group. The mean time from MI to cell
therapy was 6.26  6.42 years for younger patients
and 15.43  9.23 years for the older group (p ¼
0.0002).
Baseline characteristics are shown and compared
between age groups in Table 1. The majority of the
cohort was male (89.8%). A borderline statistically
signiﬁcant difference was observed between age
groups for the baseline 6MWD test (p ¼ 0.0561). Scar
size as a percentage of LV mass was signiﬁcantly
different between age groups at baseline (p ¼ 0.0041).
No other statistically signiﬁcant differences were
observed for demographic characteristics, Minnesota
Living with Heart Failure Questionnaire (MLHFQ), or
other cardiac imaging parameters.
There was a statistical trend toward reduced
functional capacity at baseline in the older age
CENTRAL ILLUSTRATION Patient Functional Capacity: 6-Min Walk Distance
This graphic representation shows the estimated mean 6-min walk distance values and individual patient values in each age group at each time
point, using a repeated-measures model. Both age groups increased similarly until 6 months post-TESI. Although the older age group plateaus
by 1 year post-TESI, average distances between age groups do not differ signiﬁcantly (p ¼ 0.954 and p ¼ 0.288 at 6 months and 1 year
post-TESI, respectively; between-group comparison). TESI ¼ transendocardial stem cell injection.
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127group, with 6MWD at baseline (418.30  14.92 m vs.
372.12  18.24 m, <60 years vs. $60 years, respec-
tively; p ¼ 0.056). A repeated-measures model was
used to estimate 6MWD at 6 months and 1 year after
transendocardial stem cell injection (TESI), which is
shown in the Central Illustration. The 6MWD
increased signiﬁcantly over time in both the younger
and older age groups (p ¼ 0.001 and p ¼ 0.038,
respectively). A repeated-measures model adjusting
for baseline 6MWD showed no signiﬁcant difference
in 6MWD between age groups across time (p ¼
0.5621). Using the estimates from the model, we
tested whether there were differences between age
groups at each of the follow-up time points. The
estimated difference at 6 months post-TESI was 1.01
(95% conﬁdence interval [CI]: 35.51 to 33.49; p ¼
0.9538) and at 1 year 18.61 (95% CI: 15.95 to 53.17;
p ¼ 0.2882).
Quality of life measured by the MLHFQ was
compared between age groups. A repeated-measuresmodel was used to estimate MLHFQ total score at 6
months and 1 year post-TESI, which is displayed in
Figure 1. Patients younger than 60 years of age
showed an improvement in MLHFQ total score over
time, although of only borderline signiﬁcance (p ¼
0.0580), whereas those 60 years of age and older
exhibited a more signiﬁcant improvement in MLHFQ
total score over time (p ¼ 0.0220). A repeated-
measures model adjusting for baseline MLHFQ total
score showed no signiﬁcant difference in total score
between age groups over time (p ¼ 0.5859). Esti-
mated differences between groups at 6 months and
1 year post-TESI were not signiﬁcant (2.74; 95%
CI: 5.74 to 11.23; p ¼ 0.5237 and 0.72; 95%
CI: 9.51 to 8.07; p ¼ 0.8711, respectively). When
6MWD and MLHFQ were analyzed using the
repeated-measures model using age as a continuous
covariate, neither outcome demonstrated a signiﬁ-
cant change with increase in age (p ¼ 0.137 and p ¼
0.535, respectively).
FIGURE 1 Patient Quality of Life: Minnesota Living With Heart Failure Questionnaire
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In this graphic representation of the estimated mean Minnesota Living With Heart Failure Questionnaire, the total score values and individual
patient values in each age group at each time point are depicted, using a repeated-measures model. The total scores of both age groups
improved in a parallel fashion at 6 months post-TESI. Both groups plateaued by 1 year post-TESI with similar mean total scores on
between-group comparison (p ¼ 0.524 and p ¼ 0.871 at 6 months and 1 year post-TESI, respectively; between-group comparison).
TESI ¼ transendocardial stem cell injection.
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128Next we examined the impact of age on reduction
in MI scar size. Both age groups had a similar absolute
scar size at baseline. MI size was 26.93  15.35 g
in the younger than 60 years of age group and
21.47  13.29 g in the 60 years of age and older group
(p ¼ 0.208). When testing within-group changes from
baseline to 1 year post-TESI, patients younger than
60 years of and 60 years of age and older, both had a
signiﬁcant decrease in absolute scar size (p < 0.0001
and p < 0.0001, respectively). Furthermore, this
percentage of change over time was not signiﬁcantly
different between groups (33.44  5.41% in the
younger vs. 32.89  5.25% in the older age group;
p ¼ 0.945) (Figures 2A and 3). Scar size as a percentage
of LV mass was signiﬁcantly higher at baseline in
the younger group (22.09  13.55 g) compared with
older patients (11.79  6.06 g; p ¼ 0.004). However,
at 1 year post-TESI, the percentage of change from
baseline was signiﬁcant within both age groups(p ¼ 0.0013 in the younger age group and p < 0.0001
in the older age group). There was no signiﬁcant
difference in scar size as a percentage of LV mass
when comparing percentage of change from baseline
to 1 year post-TESI between age groups (p ¼ 0.197)
(Figure 2B).
Cardiac computed tomography– or cardiac mag-
netic resonance imaging–measured end-diastolic
volume (EDV) and sphericity index were similar be-
tween age groups at baseline (p ¼ 0.553 and p ¼
0.508, respectively). At 1 year post-TESI, within-
group changes in EDV (p ¼ 0.024) and sphericity
index (p < 0.0001) signiﬁcantly decreased in the 60
years of age and older group, but no signiﬁcant
change was observed in the younger group. Neither
EDV nor sphericity index, as a percentage of change
from baseline, differed between age groups at 1 year
post-TESI (p ¼ 0.434 and p ¼ 0.077, respectively)
(Figures 3C and 3D). Although the mean ejection
FIGURE 2 Changes in Cardiac Structure and Function 1 Year Post–Mesenchymal
Stem Cell Injection
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Note: Outlier removed with >150% change in ejection fraction.
(A) Neither age group demonstrates signiﬁcant improvement in ejection fraction. (B) Both
younger and older patients show a signiﬁcant decrease in absolute scar size, with no
difference at 1 year post-TESI. (C) Scar size as a percentage of LV mass decreases in both
age groups and do not differ at 1 year. (D, E) Sphericity index and end-diastolic volume
signiﬁcantly improve only in the older age group; however, there are no between-group
changes 1 year post-TESI. (F) The older age group shows a trend in decreased end-systolic
volume; neither end-systolic volume or ejection fraction were signiﬁcantly different
between groups at 1 year post-TESI. *p < 0.05 within-group repeated-measures analysis
of variance. LV ¼ left ventricular; TESI ¼ transendocardial stem cell injection.
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129fraction (EF) and end-systolic volume (ESV) between
groups were not different at baseline (p ¼ 0.395 and
p ¼ 0.993, respectively) or at 1 year post-TESI (p ¼
0.143 and p ¼ 0.417, respectively), there was a
borderline signiﬁcant decrease over time in ESV
within the older age group (p ¼ 0.054), that was not
replicated in the younger group. There was no sig-
niﬁcant increase in EF in either age group. Linear
regression analyses, using age as a continuous vari-
able, did not indicate any signiﬁcant association
between cardiac structure or function and age
(Table 2).
DISCUSSION
The major new ﬁnding of this study shows that
therapeutic responses to culture-expanded MSCs are
not impaired in subjects of older age. This is partic-
ularly important to the emerging ﬁeld of cell therapy
for chronic heart failure due to ICM, a disorder that
increases dramatically in incidence with age (28). If
cell therapy responses were impaired with age, this
would affect patients at greatest risk. Our ﬁndings
suggest that culture expansion of MSCs overcomes
any limitation that endogenous cells might have, and
the age of the host is not a limiting factor. These data
support developing this strategy for individuals of
advanced age, and, thus, they have major public
health implications.
Here we analyzed efﬁcacy outcomes from the
TAC-HFT (26) and POSEIDON (27) trials to test
whether older patients with chronic ICM receiving
transendocardial MSC therapy have impaired out-
comes relative to young individuals. Notably, im-
provements in functional capacity were evident at 6
months after injection and persisted to 1 year after
TESI to similar degrees in both age groups. To date,
although several studies have examined whether
donor cell age and function inﬂuence responses to
cell therapy (17,19,20), no study has tested the hy-
pothesis that recipient age diminishes the efﬁcacy of
MSC transplantation. Moreover, although previous
studies examining aging and stem cell potency have
tested bone marrow mononuclear cells (29–31) and
peripheral blood progenitor cells (32), this relation-
ship in culture-expanded MSCs has not previously
been explored.
The 6MWD test has been widely used to assess
functional capacity in patients with advanced heart
failure (33) and is an independent predictor of
all-cause mortality (34). We found a signiﬁcant
improvement in 6MWD in both age groups (Central
Illustration), a result that parallels the overall
results of the TAC-HFT and POSEIDON trials. Moreimportantly, the change from baseline at both 6
months and 1 year after TESI did not differ signiﬁ-
cantly between age groups. Such an improvement in
functional capacity highlights the test’s prognostic
value (35) and strongly suggests that older cell re-
cipients functionally recover just as well as younger
patients.
Findings from the TAC-HFT and POSEIDON trials
suggest that MSCs reduce infarct size over time. We
found a similar signiﬁcant decrease in absolute scar
size irrespective of age groups at 1 year post-TESI
(Figures 2 and 3). These results corroborate ﬁndings
from the POSEIDON trial in which both autologous
and allogeneic MSCs reduced infarct size over time. It
is known that MSCs secrete antiﬁbrotic matrix met-
alloproteinases (36) via paracrine signaling. Although
the reason remains mechanistically unclear, our
study demonstrates that aging in stem cell recipients
does not appear to inﬂuence the antiﬁbrotic effects of
MSC therapy. Interestingly, scar size as a percentage
of LV mass in the younger age group was almost twice
FIGURE 3 Impact of TESI on Scar Reduction
(A) Short-axis views of the mid-ventricular area of a younger patient’s heart show delayed
enhancement delineated at the anterior and septal walls. After mesenchymal stem cell
injection, the scar size in a patient younger than 60 years of age decreased from 30.9 g at
baseline to 21.2 g at 1 year with a 31.4% reduction. (B) Short-axis views of the mid-
ventricular area of the heart of a patient 60 years of age and older, with delayed
enhancement shown at the anterior and septal walls. Delayed tissue enhancement cor-
responds to scarred tissue and is depicted brighter than the nonscarred tissue (automat-
ically detected and delineated in red using the full width at half-maximum technique). Red,
green, and white lines demarcating the endocardial and epicardial contours and borders of
the segments, respectively, were drawn manually. The extent of the scar is represented by
blue arrows. After mesenchymal stem cell injection, scar size in the patient 60 years of age
and older decreased from 36.2 g at baseline to 24.5 g at 1 year, with a similar 32.3%
reduction in myocardial infarction size. TESI ¼ transendocardial stem cell injection.
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130as large as in the older age group at baseline (Table 1).
This cannot be accounted for except possibly by the
small sample size used in the study, which was
further narrowed when focusing on the younger than
60 years of age group. More importantly, the changeTABLE 2 Association Between Cardiac Structure and Age Using a
Linear Regression Model
Cardiac Imaging Parameter
Regression
Parameter Estimate SE p Value
Scar size as absolute value 0.25 0.38 0.5009
Scar size as percentage of
LV mass
0.58 0.1501
EF* — — 0.5414
EDV 0.25 0.18 0.1639
ESV 0.28 0.26 0.2777
SI 0.19 0.18 0.2831
*Due to the highly skewed distribution of the EF, a nonparametric Spearman rank
correlation coefﬁcient test was used to determine whether a signiﬁcant association
was present. Correlation coefﬁcient between age and EF ¼ 0.0957.
Abbreviations as in Table 1.from baseline to 1 year post-injection was similar
between the 2 groups.
Quality of life in each age group was similar at
baseline, and comparisons of MLHFQ total score
changes at both 6 months and 1 year from baseline did
not differ signiﬁcantly between groups (Figure 1). The
questionnaire has been deemed a valid and effective
instrument in measuring quality of life in heart fail-
ure patients (37). Composed of 21 items that sum up a
total score, ranging from 0 (no effect) to 105 (strong
effect of heart failure on daily life), the MLHFQ is a
commonly used assessment tool in heart failure
studies (38,39). Our analysis demonstrated a signiﬁ-
cant improvement in MLHFQ score in older patients
and a trend, with borderline signiﬁcance, toward an
improved total score in patients younger than 60
years of age.
Past studies (1,2) established the role of MSC ther-
apy in LV reverse remodeling. We found that LV
chamber volumes between age groups were similar at
baseline as well as 1 year post-injection, albeit a sig-
niﬁcant improvement in EDV only in patients age 60
years and older. Correspondingly, sphericity index
was reduced in the older age group, despite being the
same between groups at baseline and 1 year post-
TESI. Although these ﬁndings may not completely
corroborate those of the POSEIDON and TAC-HFT
trials, they do raise the important concept of recip-
ient age not having an inﬂuence on MSC therapy ef-
ﬁcacy. Improvements in EF have been inconsistent
throughout clinical trials of stem cell therapy (40),
and we did not ﬁnd signiﬁcant increases in either
age group. Still, 1 year post-injection, EF between
older and younger age groups was not different.
Notwithstanding these data, it is important to note
that infarct size is a stronger predictor of future
adverse cardiac events than EF (41).
STUDY LIMITATIONS. First, this work had a relatively
small sample size, which may limit conclusions from
certain measurements such as time to therapy.
Although a formal power or sample size calculation
was not performed prospectively given that the pa-
tient population originates from a ﬁxed cohort, we
note that the sample size in each of the age groups
would have 84% power to detect a difference in the
distance walked in 6 min from 33 to 10 using a 2-
sided alpha of 0.05, a relatively large difference.
Second, because this analysis is a composite of 2
different clinical trials, data from 2 different imaging
modalities were used; multidetector computed to-
mography scanning in the POSEIDON trial and both
cardiac computed tomography and cardiac magnetic
resonance in the TAC-HFT trial. We corrected for
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Aging patients
respond similarly to younger patients after receiving human
mesenchymal stem cell therapy for ischemic cardiomyopathy.
Functional capacity, quality of life, and several cardiac
function parameters may improve in these patients, even
long after myocardial infarction, highlighting their ability
to yield to mesenchymal stem cell antiﬁbrotic and
pro-myogenic effects.
TRANSLATIONAL OUTLOOK: Older patients should be
included in future clinical stem cell therapy trials. Future ran-
domized studies are required to further demonstrate equivalence
in responsiveness between older and younger recipients.
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131this by calculating the percentage of changes for
cardiac imaging measurements. Finally, the issue of
biological versus chronological age merits comment.
Researchers generally believe that biological age
predominates over chronological age and can be
assessed with molecular assays such as telomere
length (10–12). We did not incorporate this assess-
ment, as telomere length assays were not part of
either the POSEIDON or TAC-HFT study design.
Importantly, whereas most telomere studies have
correlated cellular and chronological age of donor
cells, our study does not incorporate cellular charac-
teristics of donor cells, but rather the chronological
age of recipients. Future studies are planned to
measure telomere length in both donors and
recipients.
CONCLUSIONS
Our study suggests that recipient age does not reduce
the effects of MSC therapy in patients with ICM.
Importantly, comparisons of the 6MWD test and ab-
solute scar size between age groups did not differ.
Our ﬁndings document for the ﬁrst time the rela-
tionship between advanced age and clinical outcomes
in heart failure and show an important preservation
in responses to cell therapy in a group of recipients of
advanced age. These data support ongoing clinicaltrials on cell-based therapy and the need for future
clinical investigation of MSC use in individuals of
older age groups.
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